MedPath

Dobutamine

Dobutamine Injection, USP

Approved
Approval ID

9794e9d0-c8b7-4d18-8cd1-15cc4f2a9a55

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 2, 2023

Manufacturers
FDA

Hainan Poly Pharm. Co., Ltd.

DUNS: 654561638

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Dobutamine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code14335-171
Application NumberANDA216131
Product Classification
M
Marketing Category
C73584
G
Generic Name
Dobutamine
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateJanuary 2, 2023
FDA Product Classification

INGREDIENTS (4)

SODIUM METABISULFITEInactive
Quantity: 0.2 mg in 1 mL
Code: 4VON5FNS3C
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
DOBUTAMINE HYDROCHLORIDEActive
Quantity: 12.5 mg in 1 mL
Code: 0WR771DJXV
Classification: ACTIM

Dobutamine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code14335-172
Application NumberANDA216131
Product Classification
M
Marketing Category
C73584
G
Generic Name
Dobutamine
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateJanuary 2, 2023
FDA Product Classification

INGREDIENTS (4)

SODIUM METABISULFITEInactive
Quantity: 0.2 mg in 1 mL
Code: 4VON5FNS3C
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
DOBUTAMINE HYDROCHLORIDEActive
Quantity: 12.5 mg in 1 mL
Code: 0WR771DJXV
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Dobutamine - FDA Drug Approval Details